Concord Biotech Limited is an R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Concord, founded in the year 2000, has transformed from a single-product company to a broad-spectrum solution provider, offering products across diversified therapeutic segments. Concord is globally known for its products and has a commanding presence in more than 70 countries worldwide.
The company operates through three main business verticals: API manufacturing, finished formulations, and contract research and manufacturing services. Concord manufactures fermentation and semi-synthetic based products in the therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Anti-fungals & others. It is inspected & approved by regulatory certifications like USFDA, EU Japan & Korea.
Concord Biotech has three manufacturing facilities (2 for APIs & 1 for Formulations) in the vicinity of Ahmedabad in India that manufacture high quality, complex and differentiated APIs & Formulations. The company's manufacturing setup includes two API manufacturing facilities at Dholka and Limbasi, and one formulation facility at Valthera.
Unit III (Limbasi): Established in 2021, the Limbasi facility is an API manufacturing facility. Spread across 596,309 sq.m., it comprises 19 manufacturing blocks, including 6 fermentation blocks and 13 downstream processing blocks. The Limbasi facility has 24 fermenters, 30 m3 each, in the six fermentation blocks, as well as seed fermenters. It has an aggregate fermentation capacity of 800 m3.
Concord Biotech has a Market Cap of ₹18,179 Crore (up 3.21% in 1 year), a Revenue of ₹1,200 Crore, and a Profit of ₹372 Crore. The company has demonstrated strong financial performance with consistent growth trajectories.
For the full year, net profit rose 20.62% to ₹371.64 Crore in the year ended March 2025, as against ₹308.10 Crore during the previous year ended March 2024. Sales rose 18.01% to ₹1,200.09 Crore in the year ended March 2025, as against ₹1,016.94 Crore during the previous year ended March 2024.
Net profit of Concord Biotech rose 47.75% to ₹140.39 Crore in the quarter ended March 2025, as against ₹95.02 Crore during the previous quarter ended March 2024. Sales rose 34.77% to ₹429.88 Crore in the quarter ended March 2025, as against ₹318.97 Crore during the previous quarter ended March 2024.
- Market Capitalization: Concord Biotech Ltd has a market capitalization of ₹15,795 Crore (as of May 2025).
- 52-Week Range: The Concord Biotech Ltd's 52-week high share price is ₹2,658.00 and 52-week low share price is ₹1,326.90.
- Promoter Holding: Promoter holding in Concord Biotech Ltd has gone up to 44.08% as of March 2025.
Concord is working with global pharmaceutical companies for its fermentation and semi-synthetic complex niche API's in the area of Immunosuppressant, Oncology, Antibacterial, and Antifungal segments. The company's product portfolio includes high-value APIs such as Cyclosporine, Mycophenolate Mofetil, Tacrolimus, Everolimus, and Mupirocin, among others.
Concord Biotech is a fully integrated company manufacturing Immunosuppressants formulation and supplying CKD and nephrology products in India under its own brand. The company also offers formulation development services and contract research and manufacturing services for global pharmaceutical companies.
Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share resulting into 75% ownership in Stellon Biotech Inc to expand Company's business operations in USA. Stellon Biotech Inc. is a Delaware-incorporated pharmaceutical company established in December 2024.
In a regulatory filing made yesterday, Concord Biotech said that it has received an establishment inspection report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at its API facility at Dholka from April 28, 2025, till May 2, 2025. It further said that the USFDA has officially concluded its inspection, which is now closed under 21 CFR 20.64(d)(3). This closure indicates that no regulatory action is required, and the facility is permitted to continue its operations without any restrictions.
We have dedicated R&D units for both APIs and formulations located in Dholka and Valthera. Both of them are approved by DSIR, India. Concord is providing formulation development and Contract Research & Manufacturing services in the area of fermentation & semi-synthetic based API's.
Concord is globally known for its products and has a presence in more than 70 countries worldwide with efficient distribution infrastructure in markets like the USA, Europe, Japan, Latin America, Africa, Asia, besides significant presence in Indian market. Concord Biotech is engaged in the manufacturing of APIs and FDFs, which are exported to over 50 countries globally and include those in North America, Europe, Japan, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries.
The company has established itself as a leading player in the fermentation-based biopharmaceutical sector, with a strong focus on complex, high-value products that serve critical therapeutic areas. With its robust manufacturing capabilities, global regulatory approvals, and expanding market presence, Concord Biotech continues to strengthen its position as a key supplier of specialized APIs and formulations to the global pharmaceutical industry.
